The fund will support the preclinical and clinical development of Triumvira's T cell Antigen Coupler (TAC)-T cell therapy programs. TAC01-HER2 is the company's lead product, which is currently being evaluated in a phase I/II clinical trial for patients with HER2-overexpressing solid tumors (TACTIC-2), including breast, gastric, ovarian, pancreatic, gall bladder, and non-small cell lung cancers.

The extension featured new investors, including B Capital Group, along with ATEM Capital, the Myeloma Investment Fund, the Multiple Myeloma Research Foundation's venture philanthropy subsidiary, and others, joined by significant participation from existing investors, including Leaps by Bayer, the impact investment unit of Bayer AG, and Northpond Ventures.